Martin Förster

21.4k total citations · 1 hit paper
186 papers, 3.7k citations indexed

About

Martin Förster is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Martin Förster has authored 186 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 41 papers in Molecular Biology. Recurrent topics in Martin Förster's work include Lung Cancer Treatments and Mutations (42 papers), Cancer Immunotherapy and Biomarkers (33 papers) and Lung Cancer Research Studies (19 papers). Martin Förster is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Cancer Immunotherapy and Biomarkers (33 papers) and Lung Cancer Research Studies (19 papers). Martin Förster collaborates with scholars based in United Kingdom, United States and Spain. Martin Förster's co-authors include Paul Muralt, Michael Krüger, Peter Hommelhoff, Margarita Majem, Mark Schenk, Ann L. Jackman, Ji‐Youn Han, Wu‐Chou Su, Paul Baas and Edward B. Garon and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Martin Förster

178 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

2021 201 citations Margarita Majem, Martin Förster et al. Journal of Thoracic Oncology profile →

Peers

Martin Förster

ONCOL

PRM

Mitsuaki Tatsumi Japan

Lühua Wang China

Yong Bae Kim South Korea

Kazuhiko Hayashi Japan

François Bénard Canada

Stephan Bodis Switzerland

Peter Peschke Germany

N.G. Burnet United Kingdom

Winfried Brenner Germany

Hirofumi Fujii Japan

Mitsuaki Tatsumi Japan

Martin Förster

749 ×0.5

ONCOL

727 ×0.8

959 ×1.1

PRM

613 ×1.7

483 ×1.4

Citations per year, relative to Martin Förster Martin Förster (= 1×) peers Mitsuaki Tatsumi

Countries citing papers authored by Martin Förster

Since Specialization

Citations

This map shows the geographic impact of Martin Förster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Förster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Förster more than expected).

Fields of papers citing papers by Martin Förster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Förster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Förster. The network helps show where Martin Förster may publish in the future.

Co-authorship network of co-authors of Martin Förster

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Förster. A scholar is included among the top collaborators of Martin Förster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Förster. Martin Förster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Majem, Margarita, Enric Carcereny, Bernard Doger, et al.. (2025). Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study.

Mehanna, Hisham, Piers Gaunt, Martin Förster, et al.. (2025). 1317O Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC). Annals of Oncology. 36. S768–S768.

Kong, Anthony, Amanda Kirkham, Joshua Savage, et al.. (2024). Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer. PubMed. 2(1). 6–6. 3 indexed citations

Venkatesan, Subramanian, Dionysis Papadatos-Pastos, Tanya Ahmad, et al.. (2024). Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report. JTO Clinical and Research Reports. 5(12). 100746–100746. 4 indexed citations

Sahovaler, Axel, M. McGurk, Selvam Thavaraj, et al.. (2024). Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer. Oral Oncology. 159. 107081–107081. 2 indexed citations

Man, Kenneth K. C., Shibani Nicum, Rowan Miller, et al.. (2024). The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer. The Oncologist. 29(11). e1532–e1539. 2 indexed citations

Förster, Martin, Irene Braña, Antonio López–Pousa, et al.. (2024). Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 30(17). 3726–3734. 8 indexed citations

Kipps, Emma, Kenneth K. C. Man, Martin Förster, et al.. (2023). 250P The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer. Annals of Oncology. 34. S283–S283. 3 indexed citations

Middleton, Gary, Lynley V. Marshall, Lucinda Billingham, et al.. (2023). 716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers. Annals of Oncology. 34. S494–S495. 1 indexed citations

10.

Bridgewater, John, et al.. (2023). Personalising monitoring for chemotherapy patients through predicting deterioration in renal and hepatic function. Cancer Medicine. 12(17). 17856–17865. 4 indexed citations

11.

Brown, Sarah, Samantha Hinsley, Emma Hall, et al.. (2022). A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations. Clinical Cancer Research. 28(17). 3639–3651. 4 indexed citations

12.

Olmedo, M.E., Martin Förster, Víctor Moreno, et al.. (2021). Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Investigational New Drugs. 39(5). 1275–1283. 14 indexed citations

13.

Fennell, Dean A., Sarah Danson, Penella J. Woll, et al.. (2020). Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial. Clinical Cancer Research. 26(18). 4748–4755. 13 indexed citations

14.

Khan, Khurum, Jayant K. Rane, David Cunningham, et al.. (2018). Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer. 18(1). 64–71.e1. 11 indexed citations

15.

Dillon, Magnus T., Lorna Grove, Kate Newbold, et al.. (2018). Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. Clinical Cancer Research. 25(2). 487–495. 14 indexed citations

16.

Kristeleit, Rebecca, Martin Förster, J.E. Ang, et al.. (2009). Activity of BIBW 2992, an oral irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer. Journal of Thoracic Oncology. 4(9). 4 indexed citations

17.

Pillai, Radhakrishna G., Martin Förster, Meg Perumal, et al.. (2008). Imaging Pharmacodynamics of the α-Folate Receptor–Targeted Thymidylate Synthase Inhibitor BGC 945. Cancer Research. 68(10). 3827–3834. 30 indexed citations

18.

McCloskey, Eugène, M.N.C. Benéton, D Charlesworth, et al.. (2006). Clodronate Reduces the Incidence of Fractures in Community-Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double-Blind, Placebo-Controlled Randomized Study. Journal of Bone and Mineral Research. 22(1). 135–141. 151 indexed citations

19.

Gibbs, David D., Davinder S. Theti, Matthew Green, et al.. (2005). BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing Tumors. Cancer Research. 65(24). 11721–11728. 86 indexed citations

20.

Lücke, Klaus, Martin Förster, & H. Laqua. (1987). [Long-term experience using an intraocular silicone oil filling].. PubMed. 84(1). 96–8. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact